ABBV-382
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABBV-382, covering 2025-05-30 to 2025-10-29. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 [Phase 2]